Nongastric marginal-zone B-cell MALT lymphoma: Prognostic value of disease dissemination

Oncologist

Volumn 11, Issue 3, 2006, Pages 285-291

  Arcaini, Luca ^a   Burcheri, Sara ^a   Rossi, Andrea ^b   Passamonti, Francesco ^a   Paulli, Marco ^a   Boveri, Emanuela ^a   Brusamolino, Ercole ^a   Orlandi, Ester ^a   Molteni, Alfredo ^c   Pulsoni, Alessandro ^d   Cox, Maria Christina ^e   Orsucci, Lorella ^f   Fabbri, Alberto ^g   Frezzato, Maurizio ^h   Voso, Maria Teresa ⁱ   Zaja, Francesco ^j   Montanari, Francesca ^a   Pascutto, Cristiana ^a   Morra, Enrica ^c   Cortelazzo, Sergio ^b   Lazzarino, Mario ^a   more..

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g UNIVERSITY OF SIENA   (Italy)

^h SAN BORTOLO HOSPITAL   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j UNIVERSITY OF UDINE   (Italy)

more..

Author keywords

Dissemination; MALT lymphoma; Marginal zone; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW METASTASIS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE B CELL MALT LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIVARIATE ANALYSIS; ORBIT CANCER; PRIORITY JOURNAL; PROGNOSIS; SALIVARY GLAND CANCER; SKIN LYMPHOMA; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TONSIL CANCER; UNIVARIATE ANALYSIS; WALDEYER RING;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; LYMPHATIC METASTASIS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES;

EID: 33645080942     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-3-285     Document Type: Article

References (18)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-3918.
2. Cavalli F, Isaacson PG, Gascoyne RD et al. MALT lymphomas. Hematology (Am Soc Hematol Educ Program) 2001;241-258.
3. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology (Am Soc Hematol Educ Program) 2005;307-313.
4. Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999;17:1254-1258.
5. Thieblemont C, Berger F, Dumontet C et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95;802-806.
6. Zucca E, Conconi A, Pedrinis E et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-2495.
7. Raderer M, Vorbeck F, Formanek M et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000;83:454-457.
8. Thieblemont C, de la Fouchardiere A, Coiffier B. Nongastric mucosa-associated lymphoid tissue lymphomas. Clin Lymphoma 2003;3:212-224.
9. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. Hematol J 2000;1:53-66.
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
11. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265.
12. Tanimoto K, Kaneko A, Suzuki S et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 2006;17:135-140.
13. Suarez F, Lortholary O, Hermine O et al. Infection-associated lymphomas derived from marginal-zone B-cells: a model of antigen-driven lymphoproliferations. Blood 2006 Jan 5; [Epub ahead of print].
14. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005;23:6415-6420.
15. Raderer M, Streubel B, Woehrer S et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005;11:3349-3352.
16. Conconi A, Martinelli G, Thieblemont C et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745.
17. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
18. Raderer M, Wohrer S, Bartsch R et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:8442-8446.